Development of a new antibody drug to treatcongenital tooth agenesis

This poster presents a proposed antibody-based therapeutic strategy for the treatment of congenital tooth agenesis, a developmental dental disorder characterized by the congenital absence of one or more teeth due to genetic mutations or disruptions in key odontogenic signaling pathways. Tooth development is a highly regulated process controlled by reciprocal epithelial–mesenchymal interactions and signaling networks, including the Wnt, BMP, and SHH pathways, which are essential for tooth initiation, morphogenesis, and differentiation.

The proposed approach focuses on the use of engineered monoclonal antibodies designed to specifically target and modulate regulatory molecules within these pathways. In particular, these antibodies may act by inhibiting pathway antagonists or enhancing signaling activity, thereby restoring the balance of molecular signals required for proper tooth germ formation. By reactivating suppressed developmental signals, it may be possible to induce or rescue early stages of odontogenesis in patients with congenital absence of teeth.

Unlike conventional management options such as dental implants, bridges, or prosthetic replacements, this strategy aims to achieve true biological regeneration of teeth. It represents a shift toward regenerative and molecular-based dentistry, where developmental pathways are therapeutically manipulated to restore natural tooth formation. Although still theoretical, this concept highlights the potential of antibody engineering as a novel and promising direction in dental regenerative medicine and craniofacial biology.